TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04504812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine is a drug that is used to improve pain and function in people with knee osteoarthritis (KOA). Duloxetine is approved by the Food and Drug Administration (FDA) for the treatment of depression, anxiety disorder, fibromyalgia, and joint pain. It will be titrated up from 20 or 30mg according to a schedule provided by a study provider.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine is a drug that is used to improve pain and function in people with knee osteoarthritis (KOA). Duloxetine is approved by the Food and Drug Administration (FDA) for the treatment of depression, anxiety disorder, fibromyalgia, and joint pain. It will be titrated up from 20 or 30mg according to a schedule provided by a study provider.
Study: NCT06310213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Pressure Monitor
Description: Modified smart soft contact lens and cap with reader coil
Study: NCT05432297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive physical exercise
Description: Daily physical activity depending on daily condition
Study: NCT06097299

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection
Study: NCT05305911

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for six months
Study: NCT06097299

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT04504812

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Intra-Articular Injection
Description: Intra-Articular Injection is an injection of 3-6 milliliter (mL) hyaluronic acid (HA) mixed with 1 milliliter (mL) depo methylprednisolone (a steroid) and 2 mL 0.5% bupivacaine (an anesthetic) into the knee.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Procedure with long acting blocks
Description: People assigned to receive this will have 1 milliliter (mL) of a long-acting local anesthetic (a.k.a. liposomal bupivacaine or EXPAREL) and steroid injected into the knee.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Procedure with nerve ablation
Description: People assigned to receive this will have heat applied to destroy the nerve signaling pain in the knee. Steroid will be administered after the procedure to reduce the risk of neuritis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Coping Skills Training
Description: Participants will be provided with a written manual that includes login information for the pain coping skills training website. The participants will be expected to log into the system weekly, work through the modules, and participate in skills practice. This intervention will be conducted in combination with best practices and duloxetine.
Study: NCT05531201

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: collaboration general practitioner and physiotherapist
Description: training general practitioner and physiotherapist
Study: NCT06513624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-159
Description: ETC-159 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously.
Study: NCT04504812

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practices
Description: Best Practices can include topical or oral nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen; physical therapy that may include aquatherapy; integrative treatments such as acupuncture, yoga, or a structured exercise program; and other non-invasive treatments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practices
Description: Best Practices can include topical or oral nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen; physical therapy that may include aquatherapy; integrative treatments such as acupuncture, yoga, or a structured exercise program; and other non-invasive treatments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practices
Description: Best Practices can include topical or oral nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen; physical therapy that may include aquatherapy; integrative treatments such as acupuncture, yoga, or a structured exercise program; and other non-invasive treatments.
Study: NCT06355284

Intervention type: OTHER
Intervention: Functional MRI
Description: While in the MRI scanner, participants will complete several classic experimental tasks designed to capture brain activity related to core cognitive features of overcontrol that impact social functioning. Tasks include the Stop Signal Task (error monitoring), Delay Discounting Task (valuation, impulsivity), and Reversal Learning (cognitive flexibility).
Study: NCT06513624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab / Zoledronic Acid
Description: Denosumab will be administrated subcutaneously. Zoledronic Acid will be administered intravenously if denosumab has no response.
Study: NCT05064267

Intervention type: DIAGNOSTIC_TEST
Intervention: phlebotomy
Description: phlebotomy will be performed to obtain coagulation labs of interest. Specifically, in addition to standard clinical labs, the following will be drawn on study participants: thrombelastography with platelet mapping, antithrombin, DIC panel, factor VIII, vWF antigen, Protein C antigen and activity, Protein S antigen and activity, and ferritin.

Intervention type: DIAGNOSTIC_TEST
Intervention: phlebotomy
Description: phlebotomy will be performed to obtain coagulation labs of interest. Specifically, in addition to standard clinical labs, the following will be drawn on study participants: thrombelastography with platelet mapping, antithrombin, DIC panel, factor VIII, vWF antigen, Protein C antigen and activity, Protein S antigen and activity, and ferritin.

Intervention type: DIAGNOSTIC_TEST
Intervention: phlebotomy
Description: phlebotomy will be performed to obtain coagulation labs of interest. Specifically, in addition to standard clinical labs, the following will be drawn on study participants: thrombelastography with platelet mapping, antithrombin, DIC panel, factor VIII, vWF antigen, Protein C antigen and activity, Protein S antigen and activity, and ferritin.
Study: NCT06501209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5A-5R-based counselling session
Description: The 5As (Ask, Advise, Assess, Assist, Arrange) summarize all the activities that a healthcare provider can do to help a tobacco user (both smoking within 3-5 minutes in a primary care setting. This model can guide you through the right process to talk to respondents who are ready to quit tobacco use and deliver advice.~The 5 R's - relevance, risks, rewards, roadblocks, and repetition - are the content areas that should be addressed in a motivational counseling intervention to help those who are not ready to quit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5A-5R-based counselling session
Description: The 5As (Ask, Advise, Assess, Assist, Arrange) summarize all the activities that a healthcare provider can do to help a tobacco user (both smoking within 3-5 minutes in a primary care setting. This model can guide you through the right process to talk to respondents who are ready to quit tobacco use and deliver advice.~The 5 R's - relevance, risks, rewards, roadblocks, and repetition - are the content areas that should be addressed in a motivational counseling intervention to help those who are not ready to quit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling through mobile phone call and text message
Description: Participants will get weekly a phone call and a text message
Study: NCT05583227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab subcutaneous injection
Study: NCT06522386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Given by mouth
Study: NCT05583227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study: NCT05500599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: Intravenous Formulation of Fentanyl Citrate and Midazolam Administered Orally for Premedication
Study: NCT06522386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by mouth
Study: NCT05637671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxybutynin ER
Description: One study group will receive 10 mg of oxybutynin ER orally once daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine CR
Description: the other group will receive 12.5 mg of paroxetine CR orally once daily for 12 weeks.
Study: NCT05443360

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DENSITY™ (Amorphous calcium carbonate, ACC)
Description: 1. Dosage form: tablet~2. Dose(s): 1000 mg /tablet, comprising 500 mg amorphous calcium carbonate per tablet (calcium element 200mg)~3. Dosing schedule: The usual dose for oral use is 2 ACC tablets (400 mg calcium element) twice daily given after breakfast and dinner.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Crystalized calcium carbonate (CCC)
Description: 1. Dosage form: tablet~2. Dose(s): 1000 mg /tablet, comprising 500 mg crystalized calcium carbonate per tablet (calcium element 200mg)~3. Dosing schedule: The usual dose for oral use is 2 CCC tablets (400 mg calcium element) twice daily given after breakfast and dinner.
Study: NCT05080127

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: application of the allergenic food
Description: a small amount of the allergenic fresh food will be placed on the forearm using a patch test sticker for 15 minutes. the skin reaction will be measured.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: application of the allergenic food
Description: a small amount of the allergenic fresh food will be placed on the forearm using a patch test sticker for 15 minutes. the skin reaction will be measured.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: application of the allergenic food
Description: a small amount of the allergenic fresh food will be placed on the forearm using a patch test sticker for 15 minutes. the skin reaction will be measured.
Study: NCT04920422

Intervention type: OTHER
Intervention: No intervention
Description: Retrospective analysis using database without any intervention assigned in the study.
Study: NCT04322981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist-Led care
Description: Rapid testing in a community pharmacy, with rapid linkage to care and treatment that is pharmacist-led

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (Hepatology)
Description: Rapid testing in a community pharmacy, with standard of care referral to academic hepatology
Study: NCT06377306

Intervention type: BEHAVIORAL
Intervention: Effect of training loads and sport performance level on health and sport performance
Description: Effect of training loads and sport performance level on health and sport performance

Intervention type: BEHAVIORAL
Intervention: Effect of training loads and sport performance level on health and sport performance
Description: Effect of training loads and sport performance level on health and sport performance
Study: NCT05746962

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ScopeGuide Navigated Colonoscope
Description: colonoscopes equipped with ScopeGuide

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ScopeGuide Navigated Colonoscope
Description: colonoscopes equipped with ScopeGuide

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigation screen
Description: ScopeGuide's 3D visualisation screen
Study: NCT05049369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: Polysomnography is performed one time overnight
Study: NCT06510621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket-Shield Technique
Description: A high-speed turbine was used to cut the tooth crown 1.5-2 mm from the buccal gingival margin. The tooth was then divided along the long axis, approximately 2 mm from the buccal side(Figure 1c, 1d). The palatal roots were removed using minimally invasive elevation and extraction forceps. Next, the buccal socket-shield was trimmed to approximately 4-6 mm in height (1 mm from the buccal gingival margin)\[18\], 3-4 mm in width, and 1-1.5 mm in thickness\[19,20\]. The trimming process required with clear visualization of the shield and calibration by periodontal probe. Finally, the socket-shield was removed by minimally invasive forceps when the adjacent tooth moved proximate to the shield during the process of closing orthodontic gap.
Study: NCT05720091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-7101A 80mg
Description: a drug to treatment influenza in Chinese adults
Study: NCT04699877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Oral
Study: NCT06230991

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SIM05
Description: SIM05 contains a blend of food-grade Bifidobacterium and Lactobacillus strains plus prebiotics
Study: NCT03984188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline ER
Description: 200 mg extended release (ER) low-dose theophylline taken orally daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Manufactured methylcellulose placebo tablet taken orally daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care Treatment
Description: Per World Health Organization (WHO) guidelines for management of Chronic Obstructive Pulmonary Disease (COPD) treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Treatment
Description: Per World Health Organization (WHO) guidelines for management of Chronic Obstructive Pulmonary Disease (COPD) treatment
Study: NCT05998564

Intervention type: DEVICE
Intervention: Connecting patients to both non-invasive monitors to observe and compare the monitor's capabilities.
Description: All patients will be connected to the NOL monitor and the SCA monitor during general anesthesia.

Intervention type: DEVICE
Intervention: Connecting patients to both non-invasive monitors to observe and compare the monitor's capabilities.
Description: All patients will be connected to the NOL monitor and the SCA monitor during general anesthesia.
Study: NCT05670756

Intervention type: OTHER
Intervention: Survey
Description: Parents/guardians will complete a survey about when the medication allergy was identified and the exact symptomatology that resulted in determination of the allergy.
Study: NCT05631665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey results before and after laser treatment
Description: Determination of sexual activity rates as points with a questionnaire before and after laser treatment for patients with postmenopausal sexual function problems.
Study: NCT05272462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil
Description: Minoxidil is an antihypertensive vasodilator medication commonly used for the treatment of high blood pressure and pattern hair loss.
Study: NCT06538012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Tumor Infiltrating Lymphocytes (TIL) IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered as an intravenous (IV) infusion for five days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion
Study: NCT06253104

Intervention type: DIAGNOSTIC_TEST
Intervention: BodyMetrix Body Composition Ultrasound
Description: We will use a BodyMetrix Pro A-mode ultrasound device (BodyMetrix Pro, Intelametrix Inc., Livermore, CA) which is a lay imaging tool designed specifically to assess body composition. Images will be taken at two sites; the lateral thigh and bicep on the dominant side if able to identify, or else on the right side. On each visit, five images will be taken at each site (the lateral thigh and bicep). Participants will be measured 2-3 days from initiation in study, then 7 days after, and then weekly from the first measurement until time of advanced therapy, discharge, or death. This measurement sequence will then be repeated following advanced therapy up until discharge or death. Each measurement session will last about 20-30 minutes. This will be performed by the PI or members of the study team who have been trained by the research coordinator.
Study: NCT05722457

Intervention type: OTHER
Group type: OTHER
Intervention: external focus task focus in addition to physiotherapy and rehabilitation exercises
Description: The first study on the external focus was made in 1998 by Wulf, Ho ¨ß, \& Prinz, (1998). Focusing on the inside of the body while performing a movement is called internal (internal focus), focusing on the outside of the body is called external (external focus). Previous studies have shown that external focus is substantially more effective than internal focus in the performance of a movement.

Intervention type: OTHER
Group type: OTHER
Intervention: internal focus task focus in addition to physiotherapy and rehabilitation exercises
Description: he first study on the external focus was made in 1998 by Wulf, Ho ¨ß, \& Prinz, (1998). Focusing on the inside of the body while performing a movement is called internal (internal focus), focusing on the outside of the body is called external (external focus). Previous studies have shown that external focus is substantially more effective than internal focus in the performance of a movement.
Study: NCT05400863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: avoid sugary and NNS drinks plus start Metformin
Description: Subjects will receive education and counseling to avoid all sweetened drinks (drink water only). Participants will be asked to consume minimum of 3 drinks/day

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: avoid sugary drinks (allowed water and drinks sweetened with NNS) plus start Metformin
Description: Subjects will avoid drinks sweetened with sugar (can have diet drinks sweetened with NNS). Participants will be asked to consume minimum of 3 drinks/day
Study: NCT05691829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg solution administered intravenously every 3 weeks for 6 cycles followed by maintenance therapy until progression of disease or unacceptable toxicity (standard of care). Administered alongside chemotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: One-time, up-front radiation delivered at up to five metastatic subsites at a 4 Gy x 5 radiation dose fractionation schedule. Radiation will be delivered within five days before or after initiation of first cycle of pembrolizumab treatment. Radiation modality and technique will be determined at the discretion of the treating radiation oncologist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Administered alongside pembrolizumab every 3 weeks for 6 cycles per institutional standard of care. For non-squamous, the standard chemotherapy option of choice is carboplatin and pemetrexed. For squamous cell carcinoma, the chemotherapy used would be carboplatin and paclitaxel or nab-paclitaxel
Study: NCT05362305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Essential Coaching for Every Mother
Description: Daily text messages for the first six-weeks postpartum.
Study: NCT05910554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients randomized to metformin will be assigned the active arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: Patients randomized to cellulose will be assigned the placebo arm.
Study: NCT06062472

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Lactobacillus paracasei PS23 will be used in this study

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: heat-treated of Lactobacillus paracasei HT-PS23
Description: heat-treated probiotic capsule contain 10 billion of Lactobacillus paracasei, 2 caps daily use

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsule contains microcrystalline cellulose, 2 caps daily use
Study: NCT05063136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine+endocrine therapy
Description: Capecitabine (500mg, tid) (for 1 year)+ standard endocrine therapy (at least 5 years)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+endocrine therapy
Description: Placebo (tid) (for 1 year)+ standard endocrine therapy (at least 5 years)
Study: NCT05563844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM 8.4 mg/m2
Description: 1 case, Take the medicine once on D1,D 1-21.
Study: NCT05817344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy - Integrated
Description: A brief exposure-based psychotherapy for posttraumatic stress disorder integrated with harm reduction strategies for opioid use disorder

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy - Integrated
Description: A brief exposure-based psychotherapy for posttraumatic stress disorder integrated with harm reduction strategies for opioid use disorder
Study: NCT05668923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech sound stimulation
Description: Behavioral-, electrophysiological-, and magnetic resonance imaging-based speech sound testing
Study: NCT06132204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535 Tablets
Description: HRS-7535 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535 Tablets
Description: HRS-7535 Tablets